List view / Grid view

Targets

The diabetic measures the level of glucose in the blood. World Diabetes day, 14 November. Diabetes concept. Diabetic supplies on a blue background

Next-gen biotech: rBIO’s approach to affordable insulin solutions

4 April 2025 | By Drug Target Review

rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.

Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule. 3D rendered illustration of DNA.

article

Gene silencing: a step forward for rare disease therapy

1 April 2025 | By Dr Dan Williams (Co-founder and CEO of SynaptixBio)

Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.

news

New approach targets VHR enzyme for sepsis treatment

28 March 2025 | By Drug Target Review

A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.

tau is one of the main targets for this disease and finding new ways to target this protein could aid in the development of new Alzheimer’s treatments.

news

New drug OLX-07010 shows promise in treating tau diseases

27 March 2025 | By Drug Target Review

OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.

webinar

Solving the AOC puzzle: Strategies for chemistry, manufacturing and regulatory success

21 March 2025 | By Abzena

Join our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.

Close-up of coronavirus bacteria plastic model, micro virus and covid-19 cell bacteria. Worldwide pandemic and corona outbreak concept

news

CeSPIACE: New peptide drug blocks COVID-19 variants

20 March 2025 | By Drug Target Review

Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.

Blood clot in artery, emphasizing thrombosis, coagulation process, red blood cells, fibrin strands. Heart attack, vein disease prevention, diagnosis, treatment in healthcare. Blood clot formation 3D

article

Abelacimab: the next frontier in safer anticoagulation therapy

20 March 2025 | By Drug Target Review

Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.

webinar

Reprogramming immunity: designing smarter checkpoint receptor agonists

19 March 2025 | By Eurofins DiscoverX

Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.

A human brain on blue background. 3D illustration

article

The future of mental health treatment: Zelquistinel’s role

17 March 2025 | By Drug Target Review

Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.

article

New insights into surfactant spread for lung drug delivery

12 March 2025 | By Drug Target Review

A recent study led by Dr Richard McNair highlights the role of the Marangoni effect in surfactant spreading, offering potential improvements in drug development and delivery for lung diseases.

3D Rendering of Antibody Drug Conjugate - ADC

article

Refining and targeting exatecan with ADC technology

10 March 2025 | By Drug Target Review

DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.

Elevate healthcare with AI technology services.Virtual health care analytics empower medical professionals in the medical revolution. Data analytics enhance patient care and healthcare administration.

news

New AI algorithm searches 10 sextillion drug candidates

6 March 2025 | By Drug Target Review

Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.

article

The future of cell therapy: scaling production for global reach

6 March 2025 | By Drug Target Review

Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.

Scientists are using laptop to research cancer or covid treatment in lab. medical human body analysis technology. Scientific research with intelligent AI system innovation Develop an antiviral vaccine

news

AI-designed CDK12/13 inhibitors target resistant cancers

5 March 2025 | By Drug Target Review

Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.

Chronic lymphocytic leukemia (CLL) cells in blood flow - closeup view 3d illustration

news

Leukaemia cells hit hard by innovative dual-drug approach

4 March 2025 | By Tony Portelli - Advisory Editor

Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.

Cookie	Type	Duration	Description
cookielawinfo-checkbox-advertising-targeting	persistent	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	persistent	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	session	1 year	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	persistent	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	session	1 year	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Type	Duration	Description
advanced_ads_browser_width	persistent	1 month	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	persistent	2 years	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	persistent	1 month	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	persistent	1 year	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	persistent	2 years	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	persistent	2 years	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	persistent	3 months	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	persistent	1 month	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	persistent	5 months	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Cookie	Type	Duration	Description
bcookie	persistent	2 years	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	persistent	30 minutes	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	session	1 year	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	persistent	1 day	This cookie is set by LinkedIn and used for routing.
lissc	persistent	11 months	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	persistent	2 years	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	persistent	2 years	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	persistent	20 minutes	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	persistent	20 minutes	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	persistent	20 minutes	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	persistent	2 years	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	persistent	1 minute	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	persistent	1 day	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Type	Duration	Description
cf_ob_info	persistent	1 minute	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	persistent	1 minute	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	session	1 year	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	persistent	1 month	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	persistent	Until cleared	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	session	1 year	This cookie is set by Youtube and is used to track the views of embedded videos.

Recommended

Targets